Pancreatic Cancer Research

ResearcherUniversity of AlabamaActive in the last 2 years

Sujith Sarvesh

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2689-6568; OpenAlex author ID A5063086584. Sources: OpenAlex.

Their work

Papers
10 (first author 5, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
25
Papers, trials and grants by year

2023: 1 paper · 2024: none · 2025: 4 papers · 2026: 5 papers

Papers 10

  1. Variable efficacy of the non-covalent KRAS G12D inhibitor (MRTX-1133) with obesity in murine pancreatic cancer. Co-author DOI 10.1038/s41698-026-01493-z↗
  2. Antibody subclass deficiency accelerates tumorigenesis in genetically engineered mouse models of pancreatic cancer. First author DOI 10.1172/jci.insight.198489↗
  3. Reprogramming the pancreatic ductal adenocarcinoma microenvironment: a novel integrin-targeted cytotoxin, ProAgio, potentiates chemotherapy. First author DOI 10.1186/s12943-026-02725-3↗
  4. ProAgio, a Novel Integrin αvβ3 Targeted Cytotoxin, Suppresses Tumor Growth and Reprograms the PDAC Microenvironment First author DOI 10.64898/2026.01.15.699725↗
  5. ADT-030, a novel PDE10 inhibitor, demonstrates potent antitumor activity in pancreatic ductal adenocarcinoma Co-author DOI 10.64898/2026.02.11.705411↗
  6. Paricalcitol plus hydroxychloroquine enhances gemcitabine activity and induces mesenchymal to epithelial transition in pancreatic ductal adenocarcinoma: A sing… Co-author DOI 10.1016/j.canlet.2025.217809↗
  7. Mechanism of enhancing chemotherapy efficacy in pancreatic ductal adenocarcinoma with paricalcitol and hydroxychloroquine. Co-author DOI 10.1016/j.xcrm.2024.101881↗
  8. Paricalcitol and hydroxychloroquine modulates extracellular matrix and enhance chemotherapy efficacy in pancreatic cancer. First author DOI 10.1038/s41417-025-00967-9↗
  9. ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12943-025-02288-9↗
  10. Targeting the metabolism and immune system in pancreatic ductal adenocarcinoma: Insights and future directions. First author DOI 10.1016/j.cytogfr.2023.06.006↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Dhana Sekhar Reddy Bandi · 9 shared papers, 2023–2026 · strength 2.21
  2. Ganji Purnachandra Nagaraju · 9 shared papers, 2023–2026 · strength 2.21
  3. Bassel F. El‐Rayes · 9 shared papers, 2023–2026 · strength 2.21
  4. Mehmet Akce · 7 shared papers, 2025–2026 · strength 1.70
  5. Jeremy B. Foote · 7 shared papers, 2025–2026 · strength 1.69
  6. Ashiq Masood · 3 shared papers, 2025–2026 · strength 0.73
  7. Julienne L. Carstens · 3 shared papers, 2025–2026 · strength 0.66
  8. Karina Jin Yoon · 3 shared papers, 2025–2026 · strength 0.65
  9. Zhi-Ren Liu · 2 shared papers, 2026 · strength 0.56
  10. Yulia Y. Maxuitenko · 2 shared papers, 2025–2026 · strength 0.41
  11. Donald J Buchsbaum · 2 shared papers, 2025–2026 · strength 0.41
  12. Adam B. Keeton · 2 shared papers, 2025–2026 · strength 0.41
  13. Gary Anthony Piazza · 2 shared papers, 2025–2026 · strength 0.41
  14. Asfar Sohail Azmi · 2 shared papers, 2025–2026 · strength 0.41
  15. Upender Manne · 2 shared papers, 2025 · strength 0.38
  16. Ravi Chakra Turaga · 1 shared paper, 2026 · strength 0.29
  17. Christopher Klug · 1 shared paper, 2026 · strength 0.28
  18. Harrison Kim · 1 shared paper, 2026 · strength 0.27
  19. Midhun Malla · 1 shared paper, 2026 · strength 0.27
  20. Batoul Farran · 1 shared paper, 2023 · strength 0.24
  21. Yuvasri Golivi · 1 shared paper, 2025 · strength 0.19
  22. Cameron J. Herting · 1 shared paper, 2025 · strength 0.19
  23. Olatunji Boladale Alese · 1 shared paper, 2025 · strength 0.19
  24. Manoj Bhasin · 1 shared paper, 2025 · strength 0.19
  25. Gregory B. Lesinski · 1 shared paper, 2025 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.